LLY vs DGX
By Alex · Tickerpine
Eli Lilly and Company vs Quest Diagnostics Incorporated, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | DGX |
|---|---|---|
| Price | $1,208.12 | $209.88 |
| Market cap | $1.08T | $23.23B |
| P/E ratio | 42.9 | 23.2 |
| ROE | 107.46% | 14.54% |
| Profit margin | 34.99% | 9.08% |
| Revenue growth | 55.50% | 9.20% |
| Dividend yield | 0.57% | 1.64% |
| Beta | 0.52 | 0.59 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs DGX in plain English
- LLY is the bigger company — about 46.4× the market cap of DGX.
- DGX is cheaper on earnings (P/E 23.2 vs 42.9).
- LLY earns a higher return on equity (107% vs 15%).
- LLY is growing revenue faster (56% vs 9%).
- DGX has the higher dividend yield (1.64% vs 0.57%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
DGX return calculator
See what $1,000 in Quest Diagnostics Incorporated would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.